Annual direct and indirect costs attributable to nocturia in Germany, Sweden, and the UK.
OBJECTIVE
Our aim was to estimate the prevalence-based cost of illness imposed by nocturia (≥2 nocturnal voids per night) in Germany, Sweden, and the UK in an average year.


METHODS
Information obtained from a systematic review of published literature and clinicians was used to construct an algorithm depicting the management of nocturia in these three countries. This enabled an estimation of (1) annual levels of healthcare resource use, (2) annual cost of healthcare resource use, and (3) annual societal cost arising from presenteeism and absenteeism attributable to nocturia in each country.


RESULTS
In an average year, there are an estimated 12.5, 1.2, and 8.6 million patients ≥20 years of age with nocturia in Germany, Sweden, and the UK, respectively. In an average year in each country, respectively, these patients were estimated to have 13.8, 1.4, and 10.0 million visits to a family practitioner or specialist, ~91,000, 9000, and 63,000 hospital admissions attributable to nocturia and 216,000, 19,000, and 130,000 subjects were estimated to incur a fracture resulting from nocturia. The annual direct cost of healthcare resource use attributable to managing nocturia was estimated to be approximately €2.32 billion in Germany, 5.11 billion kr (€0.54 billion) in Sweden, and £1.35 billion (€1.77 billion) in the UK. The annual indirect societal cost arising from both presenteeism and absenteeism was estimated to be approximately €20.76 billion in Germany and 19.65 billion kr (€2.10 billion) in Sweden. In addition, in the UK, the annual indirect cost due to absenteeism was an estimated £4.32 billion (€5.64 billion).


CONCLUSIONS
Nocturia appears to impose a substantial socioeconomic burden in all three countries. Clinical and economic benefits could accrue from an increased awareness of the impact that nocturia imposes on patients, health services, and society as a whole.
Catalyst Health Economics Consultants, 34b High Street, Northwood, Middlesex, HA6 1BN, UK.
Diana
D
Weidlich
Ferring Pharmaceuticals, Copenhagen, Denmark.|Center for Medical Technology Assessment (CMT), Linköping University, Linköping, Sweden.
Fredrik L
FL
Andersson
Department of Urology, Hanover Medical School, Hannover, Germany.
Matthias
M
Oelke
Bristol Urological Institute, Bristol, UK.
Marcus John
MJ
Drake
Division of Obstetrics and Gynaecology, CLINTEC, Karolinska Institutet, Stockholm, Sweden.
Aino Fianu
AF
Jonasson
Catalyst Health Economics Consultants, 34b High Street, Northwood, Middlesex, HA6 1BN, UK. julian.guest@catalyst-health.co.uk.|Faculty of Life Sciences and Medicine, King's College, London, UK. julian.guest@catalyst-health.co.uk.
Julian F
JF
Guest
D000041:Absenteeism; D000058:Accidental Falls / Q000191:economics; D000465:Algorithms; D017281:Cost of Illness; D005060:Europe / Q000453:epidemiology; D005102:Health Expenditures / Q000706:statistics & numerical data; D006296:Health Services / Q000191:economics / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D017059:Models, Econometric; D053158:Nocturia / Q000191:economics* / Q000453:epidemiology; D015995:Prevalence
Burden; Cost; Germany; Lower urinary tract symptoms; Nocturia; Sweden; UK
BJU Int. 2002 Nov;90(7):644-8
12410740
Neurourol Urodyn. 2002;21(2):167-78
11857671
World J Urol. 2014 Oct;32(5):1155-62
25103609
Neurourol Urodyn. 2002;21(2):179-83
11857672
Maturitas. 1996 May;24(1-2):73-81
8794437
BJU Int. 2011 Jul;108(1):6-21
21676145
BJU Int. 2005 Apr;95(6):816-9
15794789
BJU Int. 2004 May;93(7):1001-4
15142151
Neurourol Urodyn. 2015 Apr;34(4):392
25640210
Eur Urol. 2010 Mar;57(3):488-96
19361907
BJU Int. 2003 Dec;92(9):948-54
14632853
J Urol. 2006 Feb;175(2):596-600
16407003
J Urol. 2007 Aug;178(2):548-51; discussion 551
17570424
Int J Urol. 2012 Apr;19(4):317-29
22239551
Curr Med Res Opin. 2008 Nov;24(11):3063-72
18826746
Eur J Neurol. 2005 Jun;12 Suppl 1:1-27
15877774
J Urol. 2011 Feb;185(2):571-7
21168875
J Am Geriatr Soc. 1992 Dec;40(12):1217-20
1447437
Low Urin Tract Symptoms. 2014 Sep;6(3):167-71
26663599
J Urol. 2011 Oct;186(4):1358-63
21855948
J Urol. 2013 Sep;190(3):953-7
23680309
Health Syst Transit. 2012;14(5):1-159
22894859
BJU Int. 2003 Feb;91(3):190-5
12581002
BJU Int. 2009 Jan;103(2):202-9
19278532